<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258947</url>
  </required_header>
  <id_info>
    <org_study_id>VVL04</org_study_id>
    <nct_id>NCT00258947</nct_id>
  </id_info>
  <brief_title>Evaluation of Take and Safety of a Smallpox Vaccine in Healthy Young Adults</brief_title>
  <official_title>Take Evaluation and Safety of Smallpox Vaccine (LISTER Strain) in Naïve Healthy Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To estimate the smallpox vaccination take rate in healthy young adults not previously&#xD;
      vaccinated with a smallpox vaccine.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To describe antibody response to vaccination and evaluate the take for each subject at&#xD;
      various timepoints for each batch and pooled batches and to evaluate local signs, symptoms,&#xD;
      and overall safety in healthy young adults not previously vaccinated with a smallpox vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <enrollment type="Actual">230</enrollment>
  <condition>Smallpox</condition>
  <condition>Poxvirus Infection</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Smallpox vaccine, LISTER strain, from chick embryo cells</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 to 25 years on the day of screening&#xD;
&#xD;
          -  Informed consent form signed&#xD;
&#xD;
          -  Able to attend all scheduled visits and to comply with all trial procedures&#xD;
&#xD;
          -  For a woman, inability to bear a child or negative serum pregnancy test performed at&#xD;
             screening (Visit 01)&#xD;
&#xD;
          -  Subject entitled to national social security&#xD;
&#xD;
          -  Subject registered in the French file of healthy volunteers in clinical trials&#xD;
&#xD;
          -  For a woman of child-bearing potential: use of an effective method of contraception&#xD;
             (hormonal or barrier method) from at least 3 months prior to screening to 3 months&#xD;
             following trial vaccination&#xD;
&#xD;
          -  For a woman, inability to bear a child or negative urine pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous smallpox vaccination confirmed by vaccination record or typical scar&#xD;
&#xD;
          -  Participation in another trial in the 3 months before or during the trial period&#xD;
&#xD;
          -  Acute intercurrent or chronic illness during the trial&#xD;
&#xD;
          -  Breast-feeding&#xD;
&#xD;
          -  Allergy or sensitivity to any known components of vaccinia immune globulin or previous&#xD;
             reaction to immunoglobulins or trial vaccine&#xD;
&#xD;
          -  Congenital or acquired immunodeficiency or immunosuppressive therapy or any treatment&#xD;
             including corticosteroids&#xD;
&#xD;
          -  Treatment with antiviral drugs within 1 month before vaccination&#xD;
&#xD;
          -  History of organ or bone marrow transplant or skin disorders&#xD;
&#xD;
          -  Personal or family history of autoimmune disease or cardiac disease, including cardiac&#xD;
             risk factors&#xD;
&#xD;
          -  History or current central nervous system disease&#xD;
&#xD;
          -  Ongoing acute infectious disease&#xD;
&#xD;
          -  Blood or blood-derived products received in the past 6 months&#xD;
&#xD;
          -  Any vaccination with a live-attenuated vaccine within the 60 days or other vaccines&#xD;
             within 40 days preceding the trial vaccination&#xD;
&#xD;
          -  Vaccination planned in the 8 weeks following the trial vaccination&#xD;
&#xD;
          -  Planned or foreseeable close contact after vaccination with infants less than 12&#xD;
             months, or with immuno-suppressed persons, pregnant and/or lactating woman, or&#xD;
             practice of contact or water sports after vaccination before the crust separates&#xD;
&#xD;
          -  Skin wound near the vaccination site&#xD;
&#xD;
          -  Apparent lack of personal hygiene&#xD;
&#xD;
          -  Subject deprived of freedom by an administrative or court order, or in an emergency&#xD;
             setting, or hospitalized without his/her consent&#xD;
&#xD;
          -  HIV, hepatitis B or hepatitis C seropositivity (screening tests)&#xD;
&#xD;
          -  Abnormal lab values for hematological parameters or cardiac enzyme (screening tests)&#xD;
&#xD;
          -  Feverish illness (oral temperature &gt;=37.5°C, rectal equivalent temperature &gt;=38.0°C)&#xD;
             on the day of vaccination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Gieres</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lagord</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>November 24, 2005</study_first_submitted>
  <study_first_submitted_qc>November 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2005</study_first_posted>
  <last_update_submitted>January 30, 2012</last_update_submitted>
  <last_update_submitted_qc>January 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smallpox</keyword>
  <keyword>Orthopoxvirus</keyword>
  <keyword>Poxvirus</keyword>
  <keyword>Vaccina Virus</keyword>
  <keyword>LISTER Strain</keyword>
  <keyword>Bioterrorism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Smallpox</mesh_term>
    <mesh_term>Poxviridae Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

